探讨TRAB检测在Grave's病中的临床意义  

Study the Clinical significance of TRAB in Patients with Graveis Disease

作　　者：招钜泉[1] 张少丰[1] 

机构地区：[1]佛山市第一人民医院检验科,广东佛山528000

出　　处：《国际医药卫生导报》2005年第2期89-91,共3页International Medicine and Health Guidance News

摘　　要：目的 探讨促甲状腺激素受体抗体(TRAB)与毒性弥漫性甲状腺肿(Grave's病)的内 在联系,了解其活性与Graves病的关系。方法 用放射受体分析法检测Grave's病患者、其它类 型甲亢病患者及健康对照组的血清TRAB。结果Grave's病组TRAB的阳性率为63.8％,明显高于 其余两组(P<0.05);Grave's病在发病期和控制期TRAB、FT3、FT4分别为(35.6±32.0)U/L、 (16.21±10.24)pmol/L和(65.42±55.58)pmol/L和(3.9±2.7)U/L、(5.71±2.31)pmol/ L和(18.64±9.37)pmol/L,发病期明显高于控制期(P<0.05)。结论 TRAB不是Grave's病的 一个重要诊断指标,而且动态检测TRAB、FT3、FT4对Grave's病的疗效监测具有重要的临床意义。Objective To investigate the interrelation of thyrotropin receptor antibody TRAB and Diffuse Toxic Goiter (Grave' s disease). Methods The serum levels of TRAB in patients with the Grave disease, the other hyperthyroidism patients and the heathy persons were measured by radio-receptor assay. Results The TRAB-Positive rate of the Grave's patient group was 63.8%. It significantly higher than that of the two groups . the levels of TRAB, FT3,FT4 in invasion stage were (35.6±32.0) U/L,(16. 21±10.24)pmol/L,(65.42±55.58) pmol/L and (3.9±2.7) U/L, (5.71±2. 31) pmol/L, (18.64±9.37) pmol/L in controlled period, there was significant difference(P<0.05). Conclusions TRAB is an important sign of Grave' s disease. Detection of levels of TRAB,FT3,FT4 had important significance in monitoring the therapeutic efficacy with Grave' s disease.

关 键 词：促甲状腺激素受体抗体(TRAB) 毒性弥漫性甲状腺肿(Grave’s病) 放射受体分析法 

分 类 号：R581.1[医药卫生—内分泌]